Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517727 | 1.00 | UCHL1 (0.35) | UCHL1EGFRSNCAALDH1A1PTPN11 | |
| SCHEMBL23328571 | 0.85 | EGFR (0.39) | UCHL1EGFRSNCAALDH1A1CA1 | |
| SCHEMBL25183818 | 0.83 | EGFR (0.31) | UCHL1EGFR | |
| SCHEMBL6375712 | 0.82 | EGFR (0.31) | EGFR | |
| SCHEMBL20836394 | 0.80 | SNCA (0.41) | UCHL1EGFRSNCAALDH1A1CA1 | |
| SCHEMBL19230506 | 0.80 | SNCA (0.41) | UCHL1EGFRSNCAALDH1A1CA1 | |
| SCHEMBL16549481 | 0.79 | CYP1A2 (0.35) | ALDH1A1 | |
| SCHEMBL18590379 | 0.79 | LMNA (0.34) | ALDH1A1 | |
| SCHEMBL20595562 | 0.77 | EGFR (0.34) | UCHL1EGFRSNCALPLLIPG | |
| SCHEMBL12324415 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250362134-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3724189-B1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132691-A1 | OLIGOMER-CONTAINING SUBSTITUTED AROMATIC TRIAZINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572797-B2 | Amino substituted pyrazine derivatives for the treatment of pain | PFIZER INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | PFIZER, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2007052123-A2 | PYRAZINE DERIVATIVES AS SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | PFIZER LIMITED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174660-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | UCHL1 2743/4885EGFR 142/4885SNCA 3744/4885 |
| US-20070105872-A1 | N-[6-amino-5-(2,3-dichlorophenyl)pyrazin-2-yl]-3-methylisoxazole-4-carboxamide; N-[6-amino-5-(2,3-dichloro-5-methoxyphenyl)pyrazin-2-yl]-1-methyl-1H-pyrazole-5-carboxamide | P2RX5, P2RX3, AADAC | UCHL1 3947/4885EGFR 4199/4885SNCA 1941/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | UCHL1 3627/4885EGFR 356/4885SNCA 3413/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | UCHL1 2743/4885EGFR 142/4885SNCA 3744/4885 |
| US-20250057817-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | UCHL1 2743/4885EGFR 142/4885SNCA 3744/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | UCHL1 2743/4885EGFR 142/4885SNCA 3744/4885 |
| US-20090048306-A1 | PYRIDINE DERIVATIVES | SDHA, P2RX4, P2RX3 | UCHL1 4700/4885EGFR 4052/4885SNCA 945/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | UCHL1 2743/4885EGFR 142/4885SNCA 3744/4885 |
| US-11905281-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | UCHL1 2743/4885EGFR 142/4885SNCA 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.